Artiva Biotherapeutics (ARTV) Enterprise Value (2024 - 2026)

Artiva Biotherapeutics (ARTV) has reported Enterprise Value for 4 consecutive years, with -$152.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 8.04% year-over-year to -$152.6 million; the TTM figure through Mar 2026 stood at -$152.6 million (up 8.04% YoY), while the FY2025 annual figure was -$108.0 million, up 41.75% from the prior year.
• Enterprise Value eased to -$152.6 million in Q1 2026 per ARTV's latest filing, from -$108.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at $73.1 million in Q2 2024 and bottomed at -$220.5 million in Q3 2025.
• Historically, Enterprise Value has averaged -$99.7 million across 4 years, with a median of -$125.2 million in 2025.
• On a YoY basis, Enterprise Value climbed as much as 236.14% in 2024 and fell as far as 1036.69% in 2024.
• Artiva Biotherapeutics' Enterprise Value stood at $19.8 million in 2023, then slumped by 1036.69% to -$185.4 million in 2024, then jumped by 41.75% to -$108.0 million in 2025, then plunged by 41.31% to -$152.6 million in 2026.
• Business Quant data shows ARTV's Enterprise Value at -$152.6 million in Q1 2026, -$108.0 million in Q4 2025, and -$220.5 million in Q3 2025.